Lungs News and Research

RSS

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

Combination of MET and erlotinib delays lung cancer progression: Study

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

FDA issues CRL for AZ-004 NDA application

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato loxapine), submitted as Adusuve Staccato (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

BARDA awards $4.2 million contract to Menssana Research to develop breath test for radiation exposure

The Biomedical Advanced Research and Development Authority in the US Department of Health and Human Services has awarded Menssana Research Inc., a company with research facilities in the NJIT Enterprise Development Center, a contract for $4.2 million to develop a breath test for radiation exposure. If the contract is exercised with options, it could total $22.84 million.

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and was published in Cancer Prevention Research, on October 5, 2010.

11 Oct 2010

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Many drug-resistant infections are the result of bacterial biofilms, structured aggregates of bacteria that live on surfaces and that are extremely resistant to environmental stresses. These biofilms impact human health in many ways - cystic fibrosis, for example, is a disease in which patients die from airway bacterial biofilm infections that are invulnerable to even the most potent antibiotics.

11 Oct 2010

Experts meet on ESMO Congress to bring new hope to cancer patients

"A congress of records," is how Professor David J. Kerr, President of the European Society for Medical Oncology described the 35th ESMO Congress, at the opening press conference for the biggest medical oncology event in Europe. "We have had record numbers of submitted and accepted abstracts and are expecting a record number of attendees." The ESMO meeting brings together cancer specialists, patients, industry representatives and members of the media. The 35th ESMO Congress takes place at Fiera Milano City, in Milan, Italy, from 8 to 12 October 2010.

8 Oct 2010

Low-fat diet reduces risk of heart disease

Losing weight, especially among adults who are very heavy to obese, is a good way to prevent the onset of atherosclerosis, the artery-thickening condition that leads to potentially deadly heart disease. A diet that is low in either fats or carbohydrates can help reduce weight. But which one is the more heart-healthy?

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

Biomoda extends pilot clinical trial of CyPath assay for early-stage lung cancer detection

Cancer diagnostics company Biomoda, Inc. today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.

8 Oct 2010

Researchers develop new technique to detect lung cancer

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

8 Oct 2010

Cs-131 brachytherapy seed implant can treat metastasized cancer

IsoRay, Inc. announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer. Initially used to treat primary cancers, Cs-131 seeds are now being used to treat metastasized cancer.

7 Oct 2010

Study shows radioembolisation with TheraSphere effective for primary liver cancer

MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.

7 Oct 2010

Majority of cancer patients are concerned about treatment costs: MDLinx

Ninety five percent of the nation's oncologists report a rise in their patients' concerns over treatment costs in the past six months, according to a survey conducted by MDLinx, one of the U.S.'s largest doctor portals.

7 Oct 2010

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

7 Oct 2010

HHS partners with PEPFAR to invest $130M for African medical education

The U.S. Department of Health and Human Services is partnering with the U.S. President's Emergency Plan for AIDS Relief with a plan to invest $130 million over five years to transform African medical education and dramatically increase the number of health care workers.

7 Oct 2010

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades.

7 Oct 2010

Lungs News and Research

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Combination of MET and erlotinib delays lung cancer progression: Study

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

FDA issues CRL for AZ-004 NDA application

BARDA awards $4.2 million contract to Menssana Research to develop breath test for radiation exposure

Abbott to withdraw Meridia medicine from the U.S. market

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Experts meet on ESMO Congress to bring new hope to cancer patients

Low-fat diet reduces risk of heart disease

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

Biomoda extends pilot clinical trial of CyPath assay for early-stage lung cancer detection

Researchers develop new technique to detect lung cancer

Cs-131 brachytherapy seed implant can treat metastasized cancer

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Majority of cancer patients are concerned about treatment costs: MDLinx

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

HHS partners with PEPFAR to invest $130M for African medical education

Pharmaxis receives FDA approval to market ARIDOL Test Kit

The ultimate guide to lung research tools and protocols eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News